Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

NCT02294006 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Well Differentiated Pancreatic Endocrine Tumor

Interventions

DRUG: Everolimus plus Octreotide LAR plus Metformin

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano